| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/01/2009 | CN101396367A Use of marsdenia tenacissima new glycoside B in preparing medicine for treating tumor disease and preparation method thereof |
| 04/01/2009 | CN101396366A Solid oral preparation containing valsartan and preparation method thereof |
| 04/01/2009 | CN101396365A Uses of 2-[piperidinyl] methyl-2, 3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one |
| 04/01/2009 | CN101396364A Zaleplon oral-cavity administration system or composition and preparation method thereof |
| 04/01/2009 | CN101396363A Composite antibacterial drugs composition containing abafungin |
| 04/01/2009 | CN101396362A Use of benzhexol hydrochloride in withdrawal and treatment of opium poison |
| 04/01/2009 | CN101396361A Medicine composition containing L-carnosine for suspending the development of the cataract |
| 04/01/2009 | CN101396360A Medicine lotion for treating skin or scalp superficial part mycotic infection and preparation method thereof |
| 04/01/2009 | CN101396359A Use of alkaloids compound in preparing medicine for treating cough |
| 04/01/2009 | CN101396358A Oxiracetam injection |
| 04/01/2009 | CN101396357A Use of lipoamide in preventing and treating insulin resistance |
| 04/01/2009 | CN101396356A New use of bilobalide |
| 04/01/2009 | CN101396355A Use of bilobalide B in preparing medicine for promoting nerve cell regenerate |
| 04/01/2009 | CN101396354A Stable taxabe compound liquid combination and preparation method and use thereof |
| 04/01/2009 | CN101396353A Use of baclofen in withdrawal treatment of opium drug |
| 04/01/2009 | CN101396352A Compositions and methods for treating amyloidosis |
| 04/01/2009 | CN101396351A Drug-loaded polyelectrolyte capsules in response to phosphatase concentration and preparation method thereof |
| 04/01/2009 | CN101396350A Clopidogrel hydrogen sulfate dispersible tablets and preparation method thereof |
| 04/01/2009 | CN101396348A Omeprazole enteric-coated micro-pill |
| 04/01/2009 | CN101396346A Paclitaxel lipid composite |
| 04/01/2009 | CN101396345A Sinomenine hydrochloride sustained-released injection and preparation method thereof |
| 04/01/2009 | CN101396344A Paeonol microemulsion preparation and preparation method thereof |
| 04/01/2009 | CN101396343A Paclitaxel submicron emulsion using lipid composite as middle carrier |
| 04/01/2009 | CN101396342A Anti-cancer sustained-released injection containing epothilone derivate |
| 04/01/2009 | CN101396340A Anti-cancer sustained-released injection containing epothilone derivate |
| 04/01/2009 | CN101396339A Novel degradable lacrimal passage plug and preparation method thereof |
| 04/01/2009 | CN101396338A Sustained-release injection containing methotrexate and synergist thereof |
| 04/01/2009 | CN101396336A Preparation technique of vitamin C fat powder coating |
| 04/01/2009 | CN101396335A Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| 04/01/2009 | CN101396334A Curcumin lipid carrier and preparation method thereof |
| 04/01/2009 | CN101396333A Eye in-situ gel of chiral anti-glaucoma medicine L-3alpha alkyla acyloxy-6belta alkyla acyloxy tropane and preparation method thereof |
| 04/01/2009 | CN101396115A Xylo-oligosaccharide stomach-invigorating intestine-moisturizing oral liquid and preparation method thereof |
| 04/01/2009 | CN101396068A Carotenoid preparation and use thereof and feedstuff containing the preparation and preparation method thereof |
| 04/01/2009 | CN101396020A Preparation method of composition containing dihydro nepetalactone |
| 04/01/2009 | CN100473673C Acrylamide crosslinking copolymer emulsion and preparation method thereof |
| 04/01/2009 | CN100473670C Alcohol water-soluble resin and method for making the same |
| 04/01/2009 | CN100473661C Novel dammarane sapogenins, use thereof as anti-cancer agents, and a process for producing the same |
| 04/01/2009 | CN100473654C S type 4-substituted hydroxypyranoindolidine compound and derivatives and preparation thereof |
| 04/01/2009 | CN100473651C Pyrazolyl-substituted heterocycles and use thereof as phytosanitary products |
| 04/01/2009 | CN100473648C 1,2,4-triazole derivatives containing a sulphamate group as aromatase inhibitors |
| 04/01/2009 | CN100473644C 9-substituted minocycline compounds |
| 04/01/2009 | CN100473416C Preparation of Chinese traditional medicine for treating gastric disease, and preparation method thereof |
| 04/01/2009 | CN100473415C Health-care product for treating cardiovascular and cerebralvascular disease |
| 04/01/2009 | CN100473387C Calf serum de-protein injection and producing method thereof |
| 04/01/2009 | CN100473386C Composition of Essentiale Phospholipids injection and preparation method thereof |
| 04/01/2009 | CN100473385C Process for dissolving 3,5-substituted oxazolidone |
| 04/01/2009 | CN100473384C Pharmaceutical formulations comprising an immune response modifier |
| 04/01/2009 | CN100473383C Pharmaceutical composition for promoting angiogenesis |
| 04/01/2009 | CN100473382C Oral dosage form for propiverine or pharmaceutically acceptable salts thereof with an extended release of the active ingredient |
| 04/01/2009 | CN100473381C Use of epothilones in the treatment of brain diseases associated with proliferative processes |
| 04/01/2009 | CN100473380C Medicine for treating tinea pedis |
| 04/01/2009 | CN100473379C Tinidazole colon positioning enteric soluble tablet |
| 04/01/2009 | CN100473378C Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof |
| 04/01/2009 | CN100473377C Process for producing soft gelatin capsule |
| 04/01/2009 | CN100473376C Stabilized aqueous suspensions for parenteral administration |
| 04/01/2009 | CN100473287C Fish fodder biological additive, and preparation and use thereof |
| 04/01/2009 | CN100473284C Additives for crustacean or fish feeds and feeds |
| 03/31/2009 | US7511175 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| 03/31/2009 | US7511173 Nutrient, foods; dietary supplements, energy drinks, and dietetic or pharmaceutical products; creatine glycinate |
| 03/31/2009 | US7511161 Dissolving crude mixture in a water immiscible solvent, washing with a dilute aqueous solution of a partial alkali salt of a polybasic acid, salt formation; simplified industrial scale synthesis and purification |
| 03/31/2009 | US7511159 Azetidine ring compounds and drugs comprising the same |
| 03/31/2009 | US7511156 Analogs of Salinosporamide A |
| 03/31/2009 | US7511152 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile |
| 03/31/2009 | US7511145 Bicyclic heteroaryl derivatives |
| 03/31/2009 | US7511144 Reverse hydroxamic acid derivatives |
| 03/31/2009 | US7511140 Process for preparing the calcium salt of rosuvastatin |
| 03/31/2009 | US7511138 Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
| 03/31/2009 | US7511137 Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
| 03/31/2009 | US7511136 Anticancer agents; antiproliferative agents; Alzheimer's disease; viricides; autoimmune diseases; central nervous system disorders |
| 03/31/2009 | US7511133 Sulfonamido derivatives with a conserved ethyl uronamide group;1-deoxy-1-[6-[[[[4-[N-(benzyl)aminosulfonyl]phenyl]amino]-carbonyl]amino]-9H-purin-9-yl]-N-ethyl- beta -D-ribofuranuronamide or derivatives; anticarcinogenic, antiinflammatory, antiischemic, antiepileptic, and hypertensive agents |
| 03/31/2009 | US7511132 Short interfering RNA sequences for use in the treatment and prevention of diabetes, alzheimer's and cancer; gene expression inhibition |
| 03/31/2009 | US7511124 immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases; kits |
| 03/31/2009 | US7511078 Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same |
| 03/31/2009 | US7511077 Aromatic derivatives of aliphatic diamines to ameliorate unwanted T-type and N-type calcium ion channel activity; stroke, pain; N-{(Z)-4-[6,6-Bis-(4-fluoro-phenyl)-hexanoylamino]-but-2-enyl}-3,4,5-trimethoxy-benzamide |
| 03/31/2009 | US7511076 Deactivated proteins |
| 03/31/2009 | US7511075 Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto |
| 03/31/2009 | US7511074 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke |
| 03/31/2009 | US7511073 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/31/2009 | US7511072 7-amido-isoindolyl compounds and methods of its use |
| 03/31/2009 | US7511071 Thioamide derivatives as progesterone receptor modulators |
| 03/31/2009 | US7511070 Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| 03/31/2009 | US7511069 Indazole compounds as β3 andrenoceptor agonist |
| 03/31/2009 | US7511068 antiinflammatory agents |
| 03/31/2009 | US7511067 3-hydroxymethyl-4-hydroxy-phenyl-derivatives for the treatment of respiratory diseases |
| 03/31/2009 | US7511066 Antithrombotic aromatic ethers |
| 03/31/2009 | US7511064 Treating conditions alleviated by 5-HT2B antagonists such as migraine, gastrointestinal disorders; restenosis, asthma, obstructive airway disease, bronchial pulmonary dysplasia, prostatic hyperplasia and priapism; hypotensive agents |
| 03/31/2009 | US7511063 High affinity quinoline-based kinase ligands |
| 03/31/2009 | US7511062 Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors |
| 03/31/2009 | US7511061 Triazoles as farnesyl transferase inhibitors |
| 03/31/2009 | US7511060 Opiate intermediates and methods of synthesis |
| 03/31/2009 | US7511059 Thiazolidinones, their production and use as pharmaceutical agents |
| 03/31/2009 | US7511058 3-benzyl-7-(4-bromo-2-chlorophenylamino)-8-chloro-[1,2,4]triazolo [4,3-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide; mitogen activated protein kinase inhibitors; used in the treatment of hyperproliferative diseases, such as cancer and inflammation in mammals; synergistic use |
| 03/31/2009 | US7511057 Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors |
| 03/31/2009 | US7511056 TGF-β inhibitors |
| 03/31/2009 | US7511055 Naphthyridin derivatives |
| 03/31/2009 | US7511054 Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs |
| 03/31/2009 | US7511053 Spiroazacyclic compounds as monoamine receptor modulators |
| 03/31/2009 | US7511052 N-[2-diethylamino-5-{N-ethyl-N-(trifluoroacetyl)amino}pyrimidin-4-yl]-L-4'-{(pyrrolidin-1-yl)carbonyloxy}phenylalanine; antiinflammatory agent; asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation |
| 03/31/2009 | US7511051 Cidofovir peptide conjugates as prodrugs |
| 03/31/2009 | US7511050 hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders |